These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 26864072)

  • 1. Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity.
    Pavel AB; Sonkin D; Reddy A
    BMC Syst Biol; 2016 Feb; 10():16. PubMed ID: 26864072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating mutation and gene expression cross-sectional data to infer cancer progression.
    Fleck JL; Pavel AB; Cassandras CG
    BMC Syst Biol; 2016 Jan; 10():12. PubMed ID: 26810975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Integrative Method Based on the Module-Network for Identifying Driver Genes in Cancer Subtypes.
    Lu X; Li X; Liu P; Qian X; Miao Q; Peng S
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29364829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.
    Cha S; Lee J; Shin JY; Kim JY; Sim SH; Keam B; Kim TM; Kim DW; Heo DS; Lee SH; Kim JI
    BMC Cancer; 2016 Feb; 16():170. PubMed ID: 26925973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression.
    Roszik J; Wu CJ; Siroy AE; Lazar AJ; Davies MA; Woodman SE; Kwong LN
    Sci Rep; 2016 Jan; 6():19649. PubMed ID: 26787600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative Data Analysis of Multi-Platform Cancer Data with a Multimodal Deep Learning Approach.
    Liang M; Li Z; Chen T; Zeng J
    IEEE/ACM Trans Comput Biol Bioinform; 2015; 12(4):928-37. PubMed ID: 26357333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive Fuzzy Consensus Clustering Framework for Clustering Analysis of Cancer Data.
    Yu Z; Chen H; You J; Liu J; Wong HS; Han G; Li L
    IEEE/ACM Trans Comput Biol Bioinform; 2015; 12(4):887-901. PubMed ID: 26357330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
    Pécuchet N; Legras A; Laurent-Puig P; Blons H
    Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Min-redundancy and max-relevance multi-view feature selection for predicting ovarian cancer survival using multi-omics data.
    El-Manzalawy Y; Hsieh TY; Shivakumar M; Kim D; Honavar V
    BMC Med Genomics; 2018 Sep; 11(Suppl 3):71. PubMed ID: 30255801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
    Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
    BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pan-cancer analysis of progression mechanisms and drug sensitivity in cancer cell lines.
    Fleck JL; Pavel AB; Cassandras CG
    Mol Omics; 2019 Dec; 15(6):399-405. PubMed ID: 31570905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICan: an integrated co-alteration network to identify ovarian cancer-related genes.
    Zhou Y; Liu Y; Li K; Zhang R; Qiu F; Zhao N; Xu Y
    PLoS One; 2015; 10(3):e0116095. PubMed ID: 25803614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bi-level and Bi-objective p-Median Type Problems for Integrative Clustering: Application to Analysis of Cancer Gene-Expression and Drug-Response Data.
    Ushakov AV; Klimentova X; Vasilyev I
    IEEE/ACM Trans Comput Biol Bioinform; 2018; 15(1):46-59. PubMed ID: 28650823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of constrained cancer driver genes based on mutation timing.
    Sakoparnig T; Fried P; Beerenwinkel N
    PLoS Comput Biol; 2015 Jan; 11(1):e1004027. PubMed ID: 25569148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia.
    Covell DG
    PLoS One; 2015; 10(7):e0127433. PubMed ID: 26132924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDENTIFY CANCER DRIVER GENES THROUGH SHARED MENDELIAN DISEASE PATHOGENIC VARIANTS AND CANCER SOMATIC MUTATIONS.
    Ma M; Wang C; Glicksberg BS; Schadt EE; Li SD; Chen R
    Pac Symp Biocomput; 2017; 22():473-484. PubMed ID: 27896999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes.
    San Lucas FA; Fowler J; Chang K; Kopetz S; Vilar E; Scheet P
    Mol Cancer Ther; 2014 Dec; 13(12):3230-40. PubMed ID: 25349306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A robust fuzzy rule based integrative feature selection strategy for gene expression data in TCGA.
    Fan S; Tang J; Tian Q; Wu C
    BMC Med Genomics; 2019 Jan; 12(Suppl 1):14. PubMed ID: 30704464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
    Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
    Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.